Grafotas 25mg Capsule contains ciclosporin, an immunosuppressive agent primarily used to prevent organ transplant rejection and to treat various autoimmune disorders. Ciclosporin acts by inhibiting calcineurin, thereby suppressing T-cell activation and reducing the immune response. This mechanism is essential in preventing the body from attacking transplanted organs such as kidneys, liver, and heart. Additionally, Grafotas is indicated for conditions like rheumatoid arthritis, psoriasis, and certain severe cases of atopic dermatitis where immune modulation is required. The 25mg dosage allows for precise titration based on patient-specific factors including weight, renal function, and the severity of the condition. Administration should be under strict medical supervision, with regular monitoring of blood ciclosporin levels to avoid toxicity. Common adverse effects include nephrotoxicity, hypertension, tremors, and increased susceptibility to infections. Patients should be advised to report any signs of infection or unusual symptoms promptly. Grafotas should be used cautiously in patients with impaired renal or hepatic function and is contraindicated in those with hypersensitivity to ciclosporin. Concomitant use with other nephrotoxic or immunosuppressive agents requires careful consideration to minimize adverse interactions. Overall, Grafotas 25mg Capsule is a critical therapeutic option in immunosuppressive therapy, necessitating vigilant clinical oversight for optimal efficacy and safety.